Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Jie Hua

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-0903-814X; OpenAlex author ID A5063913041. Sources: OpenAlex.

Their work

Papers
69 (first author 16, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
65
Papers, trials and grants by year

2018: 4 papers · 2019: 10 papers · 2020: 12 papers · 2021: 14 papers · 2022: 6 papers · 2023: 12 papers · 2024: 6 papers · 2025: 2 papers · 2026: 3 papers

Papers 50 of 69

  1. Genomic Alterations and Their Clinical Implications in Pancreatic Ductal Adenocarcinoma in a Large-Scale Chinese Cohort. First author DOI 10.1002/cam4.72083↗
  2. The CHPT-pSTAT3-SLC7A11 signaling axis controls progression and ferroptosis susceptibility of pancreatic cancer. Co-author DOI 10.1016/j.tranon.2025.102624↗
  3. ENPP1-Regulated Extracellular Purine Metabolism Drives Pancreatitis-Mediated Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2025.09.032↗
  4. SMUG1 promoted the progression of pancreatic cancer via AKT signaling pathway through binding with FOXQ1. Co-author DOI 10.1097/cm9.0000000000003640↗
  5. Dense stroma activates the TGF-β1/FBW7 axis to induce metabolic subtype switching in pancreatic cancer. Co-author DOI 10.1097/js9.0000000000002242↗
  6. Integration of single-nucleus and exosome RNA sequencing dissected inter-cellular communication and biomarkers in pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.csbj.2024.04.021↗
  7. Intratumoral CD38+CD19+B cells associate with poor clinical outcomes and immunosuppression in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.ebiom.2024.105098↗
  8. ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis. Co-author DOI 10.1016/j.redox.2024.103200↗
  9. CPT1B maintains redox homeostasis and inhibits ferroptosis to induce gemcitabine resistance via the KEAP1/NRF2 axis in pancreatic cancer. Co-author DOI 10.1016/j.surg.2023.12.019↗
  10. CircRREB1 Mediates Metabolic Reprogramming and Stemness Maintenance to Facilitate Pancreatic Ductal Adenocarcinoma Progression. Co-author DOI 10.1158/0008-5472.can-23-3596↗
  11. Identifying the risk factors for pancreatic fistula after laparoscopic pancreaticoduodenectomy in patients with pancreatic cancer. Co-author DOI 10.4240/wjgs.v16.i6.1609↗
  12. A new approach: Evaluation of necroptosis and immune status enables prediction of the tumor microenvironment and treatment targets in pancreatic cancer. First author DOI 10.1016/j.csbj.2023.03.037↗
  13. Metabolic reprogramming of cancer-associated fibroblasts in pancreatic cancer contributes to the intratumor heterogeneity of PET-CT. Co-author DOI 10.1016/j.csbj.2023.04.003↗
  14. Integrated analysis revealed hypoxia signatures and LDHA related to tumor cell dedifferentiation and unfavorable prognosis in pancreatic adenocarcinoma: Hypoxi… Co-author DOI 10.1016/j.tranon.2023.101692↗
  15. Targeting neoadjuvant chemotherapy-induced metabolic reprogramming in pancreatic cancer promotes anti-tumor immunity and chemo-response. Co-author DOI 10.1016/j.xcrm.2023.101234↗
  16. CRIP1 fosters MDSC trafficking and resets tumour microenvironment via facilitating NF-κB/p65 nuclear translocation in pancreatic ductal adenocarcinoma. Co-author DOI 10.1136/gutjnl-2022-329349↗
  17. Radical antegrade modular pancreatosplenectomy (RAMPS) versus standard retrograde pancreatosplenectomy (SRPS) for resectable body and tail pancreatic adenocarc… Co-author DOI 10.1186/s13063-023-07456-0↗
  18. Reappraisal of Tumor Deposit as a Prognostic Factor in Pancreatic Cancer. Co-author DOI 10.1245/s10434-023-13102-5↗
  19. ASO Author Reflections: Prognostic Value of Tumor Deposits in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-023-13109-y↗
  20. Cuproptosis-Related Gene DLAT as a Novel Biomarker Correlated with Prognosis, Chemoresistance, and Immune Infiltration in Pancreatic Adenocarcinoma: A Prelimin… Co-author DOI 10.3390/curroncol30030228↗
  21. Mitochondria-Related Transcriptome Characterization Associated with the Immune Microenvironment, Therapeutic Response and Survival Prediction in Pancreatic Can… Co-author DOI 10.3390/ijms24043270↗
  22. Mechanical Regulation of Redox Balance via the Induction of the PIN1/NRF2/ARE Axis in Pancreatic Cancer. Co-author DOI 10.3390/ijms24043476↗
  23. Mesenchymal Stromal Cell-Based Targeted Therapy Pancreatic Cancer: Progress and Challenges. First author DOI 10.3390/ijms24043559↗
  24. Turning towards nonimmunoreactive tumors: Evaluation of cancer-associated fibroblasts enables prediction of the immune microenvironment and treatment sensitivi… First author DOI 10.1016/j.csbj.2022.07.029↗
  25. Construction of a paclitaxel-related competitive endogenous RNA network and identification of a potential regulatory axis in pancreatic cancer. First author DOI 10.1016/j.tranon.2022.101419↗
  26. Pyroptosis-related lncRNA pairs to estimate the molecular features and prognostic outcomes of pancreatic ductal adenocarcinoma. First author DOI 10.1016/j.tranon.2022.101524↗
  27. RNA N6-methyladenosine demethylase FTO promotes pancreatic cancer progression by inducing the autocrine activity of PDGFC in an m6A-YTHDF2-dependent manner. Co-author DOI 10.1038/s41388-022-02306-w↗
  28. Comprehensive analysis of the prognosis and immune infiltration landscape of RNA methylation-related subtypes in pancreatic cancer. First author DOI 10.1186/s12885-022-09863-z↗
  29. Turning up the heat on non-immunoreactive tumors: autophagy influences the immune microenvironment in pancreatic cancer. First author DOI 10.1186/s12920-022-01371-0↗
  30. Emerging roles of the solute carrier family in pancreatic cancer. Co-author DOI 10.1002/ctm2.356↗
  31. Overcoming chemoresistance by targeting reprogrammed metabolism: the Achilles' heel of pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00018-021-03866-y↗
  32. Development and multicenter validation of a nomogram for preoperative prediction of lymph node positivity in pancreatic cancer (NeoPangram). Co-author DOI 10.1016/j.hbpd.2020.12.020↗
  33. Comment on "Prognosis-based Definition of Resectability in Pancreatic Cancer: A Road Map to New Guidelines". First author DOI 10.1097/sla.0000000000004291↗
  34. Role of tumor mutation burden-related signatures in the prognosis and immune microenvironment of pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12935-021-01900-4↗
  35. Circular RNA CircEYA3 induces energy production to promote pancreatic ductal adenocarcinoma progression through the miR-1294/c-Myc axis. Co-author DOI 10.1186/s12943-021-01400-z↗
  36. Head-to-head comparison between FOLFIRINOX and gemcitabine plus nab-paclitaxel in the neoadjuvant chemotherapy of localized pancreatic cancer: a systematic rev… Co-author DOI 10.21037/gs-21-16↗
  37. Role of LRG1 in the Cell Proliferation, Migration, and Prognosis of Pancreatic Cancer Co-author DOI 10.21203/rs.3.rs-733520/v1↗
  38. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.648917↗
  39. Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape. First author DOI 10.3389/fonc.2021.640820↗
  40. Identification of the Roles of a Stemness Index Based on mRNA Expression in the Prognosis and Metabolic Reprograming of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.643465↗
  41. Ferroptosis: At the Crossroad of Gemcitabine Resistance and Tumorigenesis in Pancreatic Cancer. Co-author DOI 10.3390/ijms222010944↗
  42. Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions. First author DOI 10.7150/ijbs.59117↗
  43. Circular RNA in pancreatic cancer: a novel avenue for the roles of diagnosis and treatment. Co-author DOI 10.7150/thno.56174↗
  44. Prognostic Value of Pancreatic Fistula in Resected Patients With Pancreatic Cancer With Neoadjuvant Therapy. First author DOI 10.1001/jamasurg.2019.5089↗
  45. AJCC 8th edition staging system for pancreatic ductal adenocarcinoma: A controversial step forward? First author DOI 10.1016/j.ejso.2019.10.009↗
  46. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. Co-author DOI 10.1080/15548627.2019.1628540↗
  47. The Strain Ratio as Obtained by Endoscopic Ultrasonography Elastography Correlates With the Stroma Proportion and the Prognosis of Local Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000002998↗
  48. Localisation of PGK1 determines metabolic phenotype to balance metastasis and proliferation in patients with SMAD4-negative pancreatic cancer. Co-author DOI 10.1136/gutjnl-2018-317163↗
  49. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Co-author DOI 10.1186/s12943-020-01167-9↗
  50. Neoadjuvant Treatment for Pancreatic Cancer: Still a Controversial Issue? First author DOI 10.1200/jco.20.00631↗

Closest collaborators

The 25 strongest of 65 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 64 shared papers, 2018–2026 · strength 9.22
  2. Si Shi · 59 shared papers, 2018–2026 · strength 8.45
  3. Qingcai Meng · 55 shared papers, 2018–2026 · strength 7.88
  4. Jin Xu · 50 shared papers, 2018–2026 · strength 6.73
  5. Chen Liang · 43 shared papers, 2018–2026 · strength 5.73
  6. Wei Wang · 27 shared papers, 2021–2026 · strength 4.52
  7. Bo Zhang · 20 shared papers, 2019–2024 · strength 3.04
  8. Miaoyan Wei · 17 shared papers, 2019–2026 · strength 2.63
  9. Rong Tang · 13 shared papers, 2020–2026 · strength 2.04
  10. Zhen Tan · 10 shared papers, 2020–2026 · strength 1.58
  11. Yiyin Zhang · 11 shared papers, 2018–2023 · strength 1.21
  12. Zeyin Rong · 6 shared papers, 2021–2026 · strength 1.10
  13. Jiang Liu · 9 shared papers, 2019–2021 · strength 0.97
  14. Qiong Du · 4 shared papers, 2023–2026 · strength 0.84
  15. Xiaomeng Liu · 6 shared papers, 2019–2023 · strength 0.77
  16. Siyuan Lu · 5 shared papers, 2022–2023 · strength 0.77
  17. Quanxing Ni · 8 shared papers, 2018–2020 · strength 0.74
  18. Jin Xu · 4 shared papers, 2022–2026 · strength 0.74
  19. Mingwei Dong · 3 shared papers, 2023–2026 · strength 0.67
  20. Jianhui Yang · 3 shared papers, 2021–2026 · strength 0.62
  21. Abudureyimu Tuerhong · 3 shared papers, 2021–2024 · strength 0.50
  22. Zengli Fang · 3 shared papers, 2020–2023 · strength 0.46
  23. Mingming Xiao · 2 shared papers, 2024–2026 · strength 0.44
  24. Liang Chen · 3 shared papers, 2021–2022 · strength 0.40
  25. Xiaoqi Mao · 2 shared papers, 2023–2024 · strength 0.39

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.